Volume 27, Issue 8 (July 2017)
Japanese

New methods for the evaluation of bone quality. Relationship between bone resorption inhibitors and bony quality. Nagai Takashi 1 , Ishikawa Koji 2 , Kuroda Takuma 2 , Oshita Yusuke 5 , Sakamoto Keizo 3 , Inagaki Katsunori 4 1Department of Orthopaedic Surgery, Showa University School of Medicine, Tokyo, Japan. 2Department of Orthopaedic Surgery, Showa University School of Medicine, Tokyo, Japan. 3Department of Orthopaedic Surgery, Showa University School of Medicine, Tokyo, Japan. 4Department of Orthopaedic Surgery, Showa University School of Medicine, Tokyo, Japan. 5Showa University Northen Yokohama Hospital, Orthopaedic Surgery, Japan. pp.1161-1167
Published Date 2017/7/28
DOI https://doi.org/10.20837/4201708103
  • Abstract
  • Look Inside
  • Reference

 Bone resorption inhibitors used in Japan are bisphosphonate, selective estrogen receptor modulators(SERMs), denosumab, eldecalcitol, and calcitonin. The structural and material properties of bone quality are important factors in osteoporosis treatment. In contrast to improvements in bone density, those in bone quality are difficult to clinically determine as no simple test is available and changes are difficult to detect. Numerous reports have been published on the mechanisms by which bone resorption inhibitors increase bone density and suppress bone fractures. This paper describes the effects of each bone resorption inhibitor and focusses on burr holes, trabeculae, microdamage, collagen cross-links, and microstructures.



基本情報

09175857.27.8.jpg
CLINICAL CALCIUM
27巻8号 (2017年7月)
電子版ISSN 印刷版ISSN 0917-5857 医薬ジャーナル社

関連文献

もっと見る

文献を共有